Regeneron Begin Period Cash Flow vs Net Income Analysis

REGN Stock  USD 716.90  20.02  2.87%   
Regeneron Pharmaceuticals financial indicator trend analysis is much more than just breaking down Regeneron Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Regeneron Pharmaceuticals is a good investment. Please check the relationship between Regeneron Pharmaceuticals Begin Period Cash Flow and its Net Income accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.

Begin Period Cash Flow vs Net Income

Begin Period Cash Flow vs Net Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Regeneron Pharmaceuticals Begin Period Cash Flow account and Net Income. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Regeneron Pharmaceuticals' Begin Period Cash Flow and Net Income is 0.81. Overlapping area represents the amount of variation of Begin Period Cash Flow that can explain the historical movement of Net Income in the same time period over historical financial statements of Regeneron Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Regeneron Pharmaceuticals' Begin Period Cash Flow and Net Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Begin Period Cash Flow of Regeneron Pharmaceuticals are associated (or correlated) with its Net Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income has no effect on the direction of Begin Period Cash Flow i.e., Regeneron Pharmaceuticals' Begin Period Cash Flow and Net Income go up and down completely randomly.

Correlation Coefficient

0.81
Relationship DirectionPositive 
Relationship StrengthStrong

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Regeneron Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Regeneron Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.
Most indicators from Regeneron Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Regeneron Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.At this time, Regeneron Pharmaceuticals' Selling General Administrative is very stable compared to the past year. As of the 13th of January 2025, Tax Provision is likely to grow to about 584.1 M, while Issuance Of Capital Stock is likely to drop about 1.3 B.
 2022 2023 2024 2025 (projected)
Total Operating Expenses5.6B7.1B8.1B8.5B
Cost Of Revenue1.6B883.7M1.0B1.1B

Regeneron Pharmaceuticals fundamental ratios Correlations

0.981.00.960.00.990.970.95-0.150.960.980.210.960.32-0.730.980.980.880.890.960.980.580.990.950.990.57
0.980.960.950.020.960.990.87-0.230.980.990.240.960.44-0.720.990.990.80.930.910.990.680.970.870.980.56
1.00.960.95-0.011.00.960.96-0.160.960.970.190.950.29-0.730.970.970.90.860.960.970.550.990.960.980.55
0.960.950.95-0.090.920.940.9-0.090.920.960.340.970.39-0.550.970.950.760.870.870.960.670.970.860.970.75
0.00.02-0.01-0.090.06-0.040.060.14-0.080.04-0.130.120.05-0.490.07-0.030.090.3-0.08-0.02-0.07-0.030.070.0-0.38
0.990.961.00.920.060.950.95-0.170.950.970.140.940.28-0.80.960.970.910.880.960.960.530.980.960.970.48
0.970.990.960.94-0.040.950.85-0.230.990.980.270.940.45-0.690.980.990.780.920.910.980.680.960.860.980.55
0.950.870.960.90.060.950.850.00.830.890.160.910.19-0.70.90.870.930.780.90.890.420.950.990.920.56
-0.15-0.23-0.16-0.090.14-0.17-0.230.0-0.31-0.13-0.020.00.050.2-0.12-0.24-0.27-0.15-0.17-0.150.06-0.14-0.06-0.150.0
0.960.980.960.92-0.080.950.990.83-0.310.970.230.910.39-0.70.960.990.780.880.930.970.650.950.840.960.52
0.980.990.970.960.040.970.980.89-0.130.970.260.970.38-0.720.990.990.790.930.930.980.660.980.880.980.56
0.210.240.190.34-0.130.140.270.16-0.020.230.260.310.210.240.280.230.050.250.130.250.270.250.090.210.49
0.960.960.950.970.120.940.940.910.00.910.970.310.44-0.670.990.940.770.940.860.970.680.960.880.970.63
0.320.440.290.390.050.280.450.190.050.390.380.210.44-0.170.440.390.050.510.180.470.770.30.160.430.25
-0.73-0.72-0.73-0.55-0.49-0.8-0.69-0.70.2-0.7-0.720.24-0.67-0.17-0.7-0.71-0.76-0.75-0.73-0.69-0.29-0.68-0.76-0.70.05
0.980.990.970.970.070.960.980.9-0.120.960.990.280.990.44-0.70.980.790.950.90.990.690.980.880.990.6
0.980.990.970.95-0.030.970.990.87-0.240.990.990.230.940.39-0.710.980.810.90.940.990.650.970.880.980.54
0.880.80.90.760.090.910.780.93-0.270.780.790.050.770.05-0.760.790.810.70.870.790.220.860.960.830.38
0.890.930.860.870.30.880.920.78-0.150.880.930.250.940.51-0.750.950.90.70.750.920.690.870.770.910.45
0.960.910.960.87-0.080.960.910.9-0.170.930.930.130.860.18-0.730.90.940.870.750.910.440.950.930.910.46
0.980.990.970.96-0.020.960.980.89-0.150.970.980.250.970.47-0.690.990.990.790.920.910.730.970.880.990.59
0.580.680.550.67-0.070.530.680.420.060.650.660.270.680.77-0.290.690.650.220.690.440.730.580.370.650.46
0.990.970.990.97-0.030.980.960.95-0.140.950.980.250.960.3-0.680.980.970.860.870.950.970.580.940.980.63
0.950.870.960.860.070.960.860.99-0.060.840.880.090.880.16-0.760.880.880.960.770.930.880.370.940.910.46
0.990.980.980.970.00.970.980.92-0.150.960.980.210.970.43-0.70.990.980.830.910.910.990.650.980.910.59
0.570.560.550.75-0.380.480.550.560.00.520.560.490.630.250.050.60.540.380.450.460.590.460.630.460.59
Click cells to compare fundamentals

Regeneron Pharmaceuticals Account Relationship Matchups

Regeneron Pharmaceuticals fundamental ratios Accounts

202020212022202320242025 (projected)
Total Assets17.2B25.4B29.2B33.1B38.0B39.9B
Total Current Liabilities2.8B3.5B3.8B3.4B3.9B4.1B
Total Stockholder Equity11.0B18.8B22.7B26.0B29.9B31.4B
Property Plant And Equipment Net3.2B3.5B3.8B4.1B4.8B5.0B
Net Debt502M(185.9M)(404.5M)(27.1M)(24.4M)(25.6M)
Retained Earnings10.9B19.0B23.3B27.3B31.3B32.9B
Cash2.2B2.9B3.1B2.7B3.1B3.3B
Non Current Assets Total4.4B4.9B7.1B13.6B15.6B16.4B
Non Currrent Assets Other328.9M555.2M(4.7B)444.1M399.7M419.7M
Cash And Short Term Investments6.7B12.5B14.3B10.8B12.5B13.1B
Net Receivables4.1B6.0B5.3B5.7B6.5B6.8B
Common Stock Shares Outstanding115.1M112.2M113.5M113.7M130.8M75.4M
Liabilities And Stockholders Equity17.2B25.4B29.2B33.1B38.0B39.9B
Non Current Liabilities Total3.3B3.2B2.7B3.7B4.2B4.4B
Other Current Assets1.2B664.8M411.2M386.6M444.6M466.8M
Other Stockholder Equity102.9M(173.4M)(404M)(1.2B)(1.4B)(1.3B)
Total Liab6.1B6.7B6.6B7.1B8.2B8.6B
Total Current Assets12.8B20.5B22.1B19.5B22.4B23.5B
Short Long Term Debt Total3.6B2.7B2.7B2.7B3.1B3.3B
Other Current Liab122.4M2.2B2.1B2.4B2.7B2.8B
Accounts Payable475.5M564M589.2M606.6M697.6M732.5M
Property Plant And Equipment Gross3.2B4.9B5.4B6.1B7.0B7.4B
Accumulated Other Comprehensive Income29.3M(26.2M)(238.8M)(80.9M)(72.8M)(69.2M)
Short Term Investments1.4B2.8B4.6B8.1B9.3B9.8B
Inventory1.9B2.0B2.4B2.6B3.0B3.1B
Other Liab889M635.5M515.3M707.8M814.0M854.7M
Other Assets2.8B555.2M747.6M(1.0)(1.15)(1.09)
Property Plant Equipment2.9B3.2B3.5B3.8B4.3B4.5B
Current Deferred Revenue577.7M442M547.7M458.9M527.7M554.1M
Net Tangible Assets11.1B11.0B18.8B21.7B25.0B26.3B
Retained Earnings Total Equity7.4B10.9B19.0B23.3B26.8B28.1B
Long Term Debt Total713.9M2.0B2.0B2.0B2.3B2.4B
Capital Surpluse4.4B6.7B8.1B9.9B11.4B12.0B

Pair Trading with Regeneron Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Regeneron Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Regeneron Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Regeneron Stock

  0.65DNLI Denali TherapeuticsPairCorr
  0.68FOLD Amicus TherapeuticsPairCorr
  0.87JNJ Johnson Johnson Earnings Call Next WeekPairCorr

Moving against Regeneron Stock

  0.9LFCR Lifecore BiomedicalPairCorr
  0.82BMY Bristol Myers SquibbPairCorr
  0.74GILD Gilead SciencesPairCorr
  0.43IMCC Im Cannabis CorpPairCorr
  0.39INCY IncytePairCorr
The ability to find closely correlated positions to Regeneron Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Regeneron Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Regeneron Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Regeneron Pharmaceuticals to buy it.
The correlation of Regeneron Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Regeneron Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Regeneron Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Regeneron Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Regeneron Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regeneron Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regeneron Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regeneron Pharmaceuticals Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.
You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.298
Earnings Share
40.42
Revenue Per Share
128.691
Quarterly Revenue Growth
0.106
Return On Assets
0.0741
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.